KIN Overview

Key Data

  • Open $9.24
  • Day Range 9.23 - 9.25
  • 52 Week Range 3.46 - 9.28
  • Market Cap $419.62M
  • Shares Outstanding 45.46M
  • Public Float 36.41M
  • Beta 1.17
  • Rev. per Employee $669.27K
  • P/E Ratio N/A
  • EPS -$1.03
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 979.32K 07/30/21
  • % of Float Shorted 2.69%
  • Average Volume 1.44M

Performance

5 Day
  • 0.00%
1 Month
  • 1.32%
3 Month
  • 92.29%
YTD
  • 114.15%
1 Year
  • 127.34%

Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 6 Full Ratings

Recent News

  • MarketWatch
  • Dow Jones

Kindred Biosciences stock price target cut to $9.25 from $15.25 at Alliance Global

Aug. 23, 2021 at 2:01 p.m. ET by Tomi Kilgore

Kindred Biosciences downgraded to neutral from buy at Alliance Global

Aug. 23, 2021 at 2:00 p.m. ET by Tomi Kilgore

Kindred Biosciences Shares Higher After News of Elanco Deal

Jun. 16, 2021 at 11:55 a.m. ET
Barron's

Elanco Strikes Deal to Better Compete With Rival Zoetis in Pet Dermatology

Jun. 16, 2021 at 10:44 a.m. ET by Barron's

Elanco Animal Health to Buy Kindred Biosciences for Roughly $440M

Jun. 16, 2021 at 6:57 a.m. ET

Elanco Animal Health to acquire Kindred Biosciences for about $440 million; Kindred shares soar 45% premarket

Jun. 16, 2021 at 6:54 a.m. ET by Ciara Linnane

Kindred Biosciences shares soar 43% premarket

Jun. 16, 2021 at 6:42 a.m. ET by Ciara Linnane

Elanco still sees Q2 revenue $1.225 bln to $1.255 bln; full-year revenue $4.670 bln to $4.710 bln

Jun. 16, 2021 at 6:41 a.m. ET by Ciara Linnane

Elanco expects deal to close in Q3

Jun. 16, 2021 at 6:40 a.m. ET by Ciara Linnane

Elanco expects deal to be 'slightly dilutive' to adj. EPS in 2021 and 2022

Jun. 16, 2021 at 6:40 a.m. ET by Ciara Linnane

Elanco Animal Health to acquire Kindred Biosciences for about $440 mln

Jun. 16, 2021 at 6:39 a.m. ET by Ciara Linnane

Kindred Biosciences Shares Up 29% After Study Results

Jun. 3, 2021 at 1:16 p.m. ET

Kindred Biosciences Shares Rise 11% on Positive Study Results

Jun. 2, 2021 at 12:59 p.m. ET

KindredBio Biosciences Trial Meets Primary Endpoint in Dogs

Jun. 2, 2021 at 9:19 a.m. ET

Kindred Biosciences stock price target cut to $10.25 from $12.50 at Alliance Global Partners

Dec. 1, 2020 at 8:21 a.m. ET by Tomi Kilgore

Kindred Biosciences stock price target cut to $8.50 from $18.00 at B. Riley FBR

Jul. 16, 2019 at 7:07 a.m. ET by Tomi Kilgore

Kindred Biosciences downgraded to neutral from buy at B. Riley FBR

Jul. 16, 2019 at 7:07 a.m. ET by Tomi Kilgore

Kindred Biosciences started at buy with $14 stock price target at Stifel Nicolaus

May. 23, 2019 at 7:31 a.m. ET by Tomi Kilgore
Barron's

The Truth About Cats: They Are a Hot Growth Area in Animal Health

Mar. 29, 2019 at 8:38 p.m. ET by Barron's

Kindred Biosciences downgraded to neutral from buy at Ladenburg Thalmann

Aug. 7, 2018 at 8:21 a.m. ET by Tomi Kilgore
  • Other News
  • Press Releases

Why Elanco Animal Health Stock Is Falling Today

Aug. 9, 2021 at 12:55 p.m. ET on Motley Fool

This Acquisition Could Open a Whole New Market to Elanco

Jul. 19, 2021 at 10:46 a.m. ET on Motley Fool

Thursday’s Pre-Market: Here’s What You Need to Know Before the Market Opens

Jun. 17, 2021 at 8:35 a.m. ET on TipRanks.com

Elanco Animal Health to Snap up Kindred Biosciences; Shares Soar

Jun. 17, 2021 at 3:21 a.m. ET on TipRanks.com

Why Kindred Biosciences Stock Skyrocketed Today

Jun. 16, 2021 at 4:20 p.m. ET on Motley Fool

Wednesday’s Pre-Market: Here’s What You Need to Know Before the Market Opens

Jun. 16, 2021 at 8:00 a.m. ET on TipRanks.com

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Jun. 16, 2021 at 7:31 a.m. ET on InvestorPlace.com

H.C. Wainwright Keeps Their Buy Rating on Kindred Biosciences (KIN)

May. 12, 2021 at 10:35 a.m. ET on SmarterAnalyst

Kindred Biosciences (KIN) Receives a Rating Update from a Top Analyst

Mar. 18, 2021 at 6:16 a.m. ET on SmarterAnalyst

These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts

Jan. 28, 2021 at 11:31 a.m. ET on TipRanks.com

H.C. Wainwright Thinks Kindred Biosciences’ Stock is Going to Recover

Dec. 15, 2020 at 6:55 a.m. ET on SmarterAnalyst

H.C. Wainwright Thinks Kindred Biosciences’ Stock is Going to Recover

Nov. 10, 2020 at 6:32 a.m. ET on SmarterAnalyst

Kindred Biosciences Inc.

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Competitors

Name Chg % Market Cap
Eli Lilly & Co. -1.14% $259.15B
Immucell Corp. -1.73% $71.61M
Phibro Animal Health Corp. -4.33% $1.03B
Heska Corp. 1.35% $2.84B
Zoetis Inc. -0.28% $98.13B
Merck & Co. Inc. -0.38% $199.17B
Competitor Data Provided ByCapital Cube Logo